Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

591.84 +13.53 (+2.34%)
Streaming Delayed Price Updated: 11:00 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
Via Benzinga
Golden Cross Appears Before argenx Investors
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: argenx Q1 Earnings
argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
Argenx SE (NASDAQ: ARGX) announced  
Via Benzinga
Recap: argenx Q4 Earnings
argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx... 
Via Benzinga
argenx's Earnings: A Preview
argenx (NASDAQ:ARGX) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
What 8 Analyst Ratings Have To Say About argenx
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi... 
Via Benzinga
What 8 Analyst Ratings Have To Say About argenx
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following an... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical... 
Via Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
What 8 Analyst Ratings Have To Say About argenx
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4... 
Via Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
From argenx
Via Business Wire
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
argenx Highlights Strategic Priorities for 2022
From argenx
Via Business Wire
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 4%
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Federal Reserve, last week... 
Via Benzinga
5 Stocks To Watch For December 20, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1.... 
Via Benzinga
The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some... 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.